StradBio |

StradBio is developing next-generation ADCs and immunotherapies for cancer and inflammatory diseases. Our lead asset, SB-230, is an anti-CD30 ADC with a novel payload and encouraging clinical activity in a Phase 1 study. The pipeline also includes SB-225, an affinity-modified anti-CD25 ADC being developed for hematological malignancies, and solid tumors. Beyond these programs, StradBio is finalizing preclinical testing of Daiad-2/15, a PD-1 and LAG-3 -dual-targeted, highly potent IL-2/IL-15 mimetic, designed to specifically activate exhausted T cells using a novel ‘AND’ logic gate. The Daiad platform can also be applied to programs for autoimmune and metabolic diseases. StradBio completed a Series A financing in October 2026 and is led by CEO Jonathan Drachman, former Chief Medical Officer of Seagen and former CEO of Neoleukin Therapeutics.

A development-stage company with two clinical assets, proven leadership, and multiple near-term value inflection points

Differentiated ADCs and engineered biologics spanning direct tumor targeting and precision immunotherapy

DIRECT TUMOR TARGETING PRECISION IMMUNOTHERAPY

SB-230¹: Next-Gen CD30 ADC

De-risked Phase 2-ready ADC with clear path to approval

Validated target with a clear development playbook
Competitive clinical efficacy and differentiated safety with high potential for regulatory and clinical success

SB-225²: Affinity-Tuned CD25 ADC

Differentiated Phase 1 ADC

Direct tumor targeting distinct from Treg-only approaches
Early evidence of potential clinical benefit in CD25+ lymphoma
Multi-indication hematology opportunity in CD25-high lymphomas and leukemia
Treg depletion in solid tumors

Daiad 2/15: PD-1/LAG-3 Cytokine Mimetic

AND-gate immune agonist

Novel conditional activation strategy
Designed to improve therapeutic index
Large immuno-oncology opportunity in a clinically validated PD-1/LAG-3 pathway

EXPERIENCED LEADERSHIP

Proven company leaders with direct ADC development and approval experience

WELL CAPITALIZED

Series A led by high-quality VCs funds clinical and regulatory execution

VALUE CREATION

Near term de-risking with long-term growth potential

¹SB-230 – Co-development with Pfizer Oncology | PF-08046044 (SGN-35C)

²SB-225 – Co-development with Pfizer Oncology | PF-08046032 (CD25V)

Team

Jonathan Drachman, MD

Chief Executive Officer and Co-Founder

Jonathan has 20 years of biotechnology experience, including 14 years at Seattle Genetics (2004-18), serving in multiple roles, including Chief Medical Officer and EVP of Research and Development. Subsequently, Jonathan was CEO and Co-Founder of Neoleukin Therapeutics, a spin-out from the Institute of Protein Design. Dr. Drachman attended Harvard Medical School and then trained in internal medicine and medical oncology at the University of Washington, where he ran an academic research lab until 2004. Jonathan has been a Board member of multiple public and private biotech companies.

Mark Branum, Ph.D

Chief Technical Officer and Co-Founder

Dr. Mark Branum is Chief Technical Officer and a Founder of StradBio and leads protein sciences, CMC and operations. An experienced leader in biopharmaceutical startup companies with 20 years of experience moving programs from research into clinical trials. Dr. Branum held leadership roles in Theraclone Sciences, OncoResponse, Immune Design and Highlight Therapeutics. Prior to his career in industry Dr. Branum earned a Ph.D in chemistry from the University of Minnesota and was a postdoctoral fellow in the laboratory of Nobel laureate Aziz Sancar.

Alexander (Sasha) Astrakhan, Ph.D

Vice President of Research

Dr. Astrakhan is the head of research at StradBio, leading the development of the Daiad split cytokine platform and novel ADC applications. With 15 years of industry experience, Dr. Astrakhan has extensive expertise in preclinical drug development for oncology and autoimmune indications. Prior to StradBio, he served in sr. research roles at Pregenen, BluebirdBio, and 2seventy bio. He obtained his PhD in Immunology from University of Washington.

Anne-Sophie Carret, MD

Senior Vice President, Clinical Development

Anne-Sophie is a physician-scientist and senior oncology executive with extensive experience shaping global clinical development and regulatory strategies for innovative cancer therapies. Prior to joining StradBio, she held leadership roles at Menarini Stemline, Pfizer and Seagen, where her responsibilities spanned development strategy, clinical execution, regulatory submissions and health authority interactions across early- and late-stage oncology programs, including PADCEV® and TIVDAK®. She brings particular expertise in antibody-drug conjugates and targeted therapies, together with a strong track record of leading multidisciplinary teams and external collaborations. Before entering the biotechnology industry, Dr. Carret built a distinguished academic career in pediatric hematology-oncology at leading Canadian and French academic institutions, combining clinical care, research, program leadership and medical education.